title: Schistosoma mansoni: susceptibility differences between male and female mice can be mediated by testosterone during early infection.
abstract: In murine Schistosoma mansoni infections, fewer adult worms develop in male than in female mice infected with the same number of cercariae. To evaluate a potential role for testosterone in this phenomenon, testosterone levels were manipulated in groups of CBA/J mice that were then infected and monitored for survival rates, worm burdens, organomegaly, and egg production. By 16 weeks of infection, more than 80% of mice in groups with low levels of testosterone (untreated females, castrated males, or carrier-treated castrates) were dead, while less than 40% of those in groups with high levels of testosterone (sham-castrated males, testosterone-treated castrates, or testosterone-treated female mice) succumbed to infection. The mean number of worms recovered from mice in the low testosterone level groups was comparable among groups, and significantly greater than that from those in high-testosterone-level groups. The degree of organomegaly observed correlated strongly with worm burden, but the number of hepatic eggs per female worm did not differ significantly between groups. When male mice were castrated or sham-castrated 5 weeks after S. mansoni infection, no significant differences in host survival occurred. Furthermore, female mice treated with testosterone demonstrated reduced worm burdens if the testosterone was given 10 days prior to infection but not if the testosterone was given 10 days or 5 weeks after infection. Thus, the host sex bias observed in parallel-infected male and female mice appears to be related to the presence of male gonadal tissue or testosterone early in infection, during the development of immature schistosomules.
authors.affiliation: Centers for Disease Control and Prevention, Public Health Service, U.S. Department of Health and Human Services, Atlanta, Georgia 30341, U.S.A.
authors.forename: M
authors.initials: M
authors.lastname: Nakazawa
authors.forename: M R
authors.initials: MR
authors.lastname: Fantappie
authors.forename: G L
authors.initials: GL
authors.lastname: Freeman
authors.forename: S
authors.initials: S
authors.lastname: Eloi-Santos
authors.forename: N J
authors.initials: NJ
authors.lastname: Olsen
authors.forename: W J
authors.initials: WJ
authors.lastname: Kovacs
authors.forename: W E
authors.initials: WE
authors.lastname: Secor
authors.forename: D G
authors.initials: DG
authors.lastname: Colley
mesh_terms: D000818:Animals; D003692:Delayed-Action Preparations; D004198:Disease Susceptibility; D005260:Female; D006529:Hepatomegaly; D007274:Injections, Intraperitoneal; D008297:Male; D051379:Mice; D008808:Mice, Inbred CBA; D009919:Orchiectomy; D012550:Schistosoma mansoni / Q000187:drug effects* / Q000502:physiology; D012555:Schistosomiasis mansoni / Q000276:immunology* / Q000378:metabolism / Q000401:mortality; D012727:Sex Characteristics; D013163:Splenomegaly; D015996:Survival Rate; D013739:Testosterone / Q000008:administration & dosage / Q000378:metabolism* / Q000494:pharmacology; D013997:Time Factors
chemical_list: D003692:Delayed-Action Preparations; D013739:Testosterone